Q: Are orodispersible tablets and oral lyophilisates interchangeable on a prescription?
A: From a clinical and patient perspective there is no difference between an orodispersible tablet and an oral lyophilisate – they are both ‘melt in the mouth’ tablets which can hasten drug action and improve adherence.
However, from a Drug Tariff and DM+D perspective they are separate and distinct generic descriptions which cannot be interchanged. Reimbursement will be based on each generic description as listed in the DT or DM+D.
In the Dictionary of Medicines and Devices the brand name Maxalt Melt 10mg has a generic description of rizatriptan 10mg oral lyophilisate sugar free. This generic description is listed in Part VIIIA of the Drug Tariff as a category C drug with remuneration based on the price of Maxalt Melt.
A prescription for rizatriptan 10mg orodispersible tablets sugar free cannot be filled with Maxalt Melt because the generic descriptions do not match – although clinically indistinguishable, you will not be reimbursed correctly for supplying the Maxalt brand. This interpretation also extends to other drugs which have both descriptions listed in the DM+D.
Further to this, as of December 2013 the distinct generic description of rizatriptan 10mg orodispersible tablets sugar free is being added to the drug tariff as a category A drug. Reimbursement for this prescription will be based on this listed price.
For a fuller discussion of orodispersible dosage forms please see our CPD-Mini article: Orodispersible formulations.
Each week we will be highlighting a popular question or issue addressed by our information services team to help keep you informed about the hot topics being discussed by other members.
If you have any questions about the Drug Tariff - send Sue a message or call Information Services on 0800 783 5709